Evidence map›Paper›PMID 39532749›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

Synthesis and preclinical evaluation of [

Haoran Liang, Zihao Chen, Chunwei Mo, Yanjiang Han, Qingxing Liu, Ganghua Tang

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Synthesis, preclinical evaluation, and clinical translation of [European journal of nuclear medicine and molecular imaging · 2026
    Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Haoran Liang *GDMPA Key Laboratory for Quality Control and Evaluation of Radiopharmaceuticals, PET Center, Department of Nuclear Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Zihao Chen *GDMPA Key Laboratory for Quality Control and Evaluation of Radiopharmaceuticals, PET Center, Department of Nuclear Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Chunwei Mo *GDMPA Key Laboratory for Quality Control and Evaluation of Radiopharmaceuticals, PET Center, Department of Nuclear Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Yanjiang HanGDMPA Key Laboratory for Quality Control and Evaluation of Radiopharmaceuticals, PET Center, Department of Nuclear Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Qingxing LiuGDMPA Key Laboratory for Quality Control and Evaluation of Radiopharmaceuticals, PET Center, Department of Nuclear Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China. smu_lqx@163.com.
Ganghua TangGDMPA Key Laboratory for Quality Control and Evaluation of Radiopharmaceuticals, PET Center, Department of Nuclear Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China. gtang0224@smu.edu.cn.ORCID 0000-0001-6288-5578

Funding

Basic and Applied Basic Research Foundation of Guangdong Province 2022A1515010072, 2020A1515011399, 2023A1515111181、2024A1515010093Guangzhou Key Research and Development Program on Agriculture and Social Development Science SL2023B03J00187Guangzhou Science and Technology Plan 2023B03J0529Medical Products Administration of Guangdong Province 2021ZDB02Nanfang Hospital Talent Introduction Foundation of Southern Medical University No. 123456, 2023G003National Natural Science Foundation of China 82371996, 91949121President Foundation of Nanfang Hospital, Southern Medical University 2022B029the National Key Research and Development Program 2022YFC2403803
6 · The paper itself

Abstract

purposeSomatostatin receptor (SSTR) antagonists have recently emerged as preferable radiotracers for SSTR-targeted imaging and therapy. This study aimed to design a novel SSTR antagonist, [

methods[

results[

conclusionThe synthesis of [

Indexed as

Fluorine RadioisotopesPositron-Emission TomographyRadiopharmaceuticalsReceptors, SomatostatinAnimalsCell Line, TumorChemistry Techniques, SyntheticHumansLigandsMiceRadiochemistryTissue DistributionFluorine RadioisotopesLigandsRadiopharmaceuticalsReceptors, SomatostatinAgonistAntagonistPET/CT imagingPharmacokinetic propertySomatostatin receptor

Identifiers

PMID39532749

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.